华蟾素注射液联合含奥沙利铂方案肝动脉化疗栓塞治疗肝癌临床疗效观察

目的探讨华蟾素注射液联合含奥沙利铂方案肝动脉化疗栓塞(TACE)治疗晚期原发性肝癌的临床疗效及毒副作用。方法将51例肝癌患者随机分为两组,联合治疗组(华蟾素注射液联合含奥沙利铂方案TACE)26例,对照组(含奥沙利铂方案TACE)25例。观察患者治疗前后临床主要症状的变化。结果联合治疗组与对照组有效率分别为65.4%和64.0%(P>0.05);联合治疗组和对照组中位疾病进展时间(TTP)分别为6.5个月和6.0个月,差异无统计学意义(P>0.05),中位总生存期(OS)分别为13个月和12个月,两组差异无统计学意义(P>0.05)。治疗后联合治疗组与对照组间血清血管内皮生长因子(VEGF)、缺氧诱导因子(HIF)-1α水平差异有统计学意义(P<0.05),联合治疗组患者的体力状况改善优于对照组(P<0.05)。两组治疗后不良反应发生率无差异,两组间常见毒副反应均为转氨酶升高、发热,不良反应均可耐受。结论华蟾素注射液联合含奥沙利铂方案TACE可作为中晚期肝癌安全有效的治疗方法。

Effect of huachansu injection sequence TACE including oxaliplatin regimen for advanced hepatocelluler carcinoma

Objective To evaluate the effecacy and the safety of huachansu injection combined with transcatheter arterial chemoembolization(TACE)including oxaliplatin for advanced hepatocelluler carcinoma(HCC).Methods Fifty-one patients with advanced HCC were randomly divided into two groups.In the combined group,26 patients received huachansu injection after TACE including oxaliplatin regimen,and 25 patients in the control group were treated with TACE including oxaliplatin alone.Results The effective rate was 65.4% in the combined group and 64.0% in control group(P>0.05).The median time to progression(TTP)of the combined group was 6.5 months,while that of the control group was 6.0 months(P>0.05).The median overall survival(OS)of the combined group as 13.0 months,and 12.0 months in control group(P>0.05).In this study,it was found that the serum VEGF and HIF-1α levels were lower significantly after treatment in combined group than that in TACE group(P<0.05).The performance status of combined group,according to KPS questionare,was higher than that of control group(P<0.05).There was no difference between two groups in side effects.The most frequent adverse effects of both groups were marrow suppession,and all adverse effects were tolerable.Conclusions Huachansu injection combined with TACE including oxaliplatin can be used as a safe and effective treatment for advanced HCC.